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Nutrition and physical activity have profound effects on skeletal muscle 
metabolism and growth. Regulation of 
muscle mass depends on a thin balance 
between growth-promoting and growth-
suppressing factors. Over the past decade, 
the mammalian target of rapamycin 
(mTOR) kinase has emerged as an essen-
tial factor for muscle growth by mediating 
the anabolic response to nutrients, insu-
lin, insulin-like growth factors and resis-
tance exercise. As opposed to the mTOR 
signaling pathway, the AMP-activated 
protein kinase (AMPK) is switched on 
during starvation and endurance exer-
cise to upregulate energy-conserving 
processes. Recent evidence indicates 
that mTORC1 (mTOR Complex 1) and 
AMPK represent two antagonistic forces 
governing muscle adaption to nutri-
tion, starvation and growth stimulation. 
Animal knockout models with impaired 
mTORC1 signaling showed decreased 
muscle mass correlated with increased 
AMPK activation. Interestingly, AMPK 
inhibition in p70S6K-deficient muscle 
cells restores cell growth and sensitiv-
ity to nutrients. Conversely, muscle cells 
lacking AMPK have increased mTORC1 
activation with increased cell size and 
protein synthesis rate. We also demon-
strated that the hypertrophic action of 
MyrAkt is enhanced in AMPK-deficient 
muscle, indicating that AMPK acts as 
a negative feedback control to restrain 
muscle hypertrophy. Our recent results 
extend this notion by showing that 
AMPKα1, but not AMPKα2, regulates 
muscle cell size through the control of 
mTORC1 signaling. These results reveal 
the diverse functions of the two catalytic 
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isoforms of AMPK, with AMPKα1 play-
ing a predominant role in the control of 
muscle cell size and AMPKα2 mediating 
muscle metabolic adaptation. Thus, the 
crosstalk between AMPK and mTORC1 
signaling is a highly regulated way to 
control changes in muscle growth and 
metabolic rate imposed by external cues.
Skeletal muscle comprises about 40–50% 
of total body mass and contributes to 
nutrient storage and supply. The major 
role of mammalian target of rapamy-
cin complex 1 (mTORC1) in regulating 
muscle mass in response to a wide range 
of upstream inputs, including nutrients, 
growth factors and insulin, has long been 
established.1 The control of muscle cell 
size by mTORC1 relies on a dynamic bal-
ance between anabolic processes, such as 
protein synthesis and nutrient storage, and 
catabolic processes, like the utilization of 
energy stores. More recently, the energy 
sensor 5'-AMP-activated protein kinase 
(AMPK), an energy-sensing kinase, has 
emerged as another key player in con-
trolling muscle cell size.2-4 Interestingly, 
AMPK directly phosphorylates TSC1/2,5 
mTOR5 and raptor,6 leading to the sup-
pression of mTORC1 signaling. AMPK 
is a monitor of cellular energy homeo-
stasis present in a wide variety of organ-
isms, from yeast to mammals.7 AMPK 
is a heterotrimeric complex, consisting 
of a catalytic α-subunit and the regula-
tory β- and γ-subunits, which functions 
as a fuel sensor to coordinate the balance 
between energy-consuming and energy-
producing processes. There are a num-
ber of isoforms known for each subunit 
(α1, α2, β1, β2, γ1, γ2, γ3), which are 
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muscle fibers. Activation of mTORC1 
in AMPK-deficient myotubes promotes 
a high protein synthesis rate, leading to 
a 1.5-fold increase in myotube diameter. 
We have also demonstrated that selective 
inactivation of mTORC1 by rapamycin 
reduces protein synthesis to control levels 
and limits cell growth, rescuing AMPK-
deficient myotube cell size.2 Mirroring 
this result, inhibition of AMPK activ-
ity in p70S6K-deficient myotubes, either 
by expression of a kinase-dead mutant 
(AMPK-KD) or by using siRNA target-
ing both α1 and α2 catalytic subunits, 
rescues p70S6K-deficient myotubes’ cell 
size, thereby highlighting the role of 
AMPK in muscle cell size control.11 In 
addition, expression of AMPK-KD in 
WT myotubes and muscle induces the 
phosphorylation of p70S6K and 4E-BP1, 
with a concomitant increase in myo-
tube diameter and fiber cross-sectional 
area, consistent with the results obtained 
with AMPK-deficient myotubes.11 Taken 
together, these studies clearly demonstrate 
the reciprocity in the crosstalk between 
AMPK and mTORC1, as downregulating 
one pathway is sufficient to upregulate the 
other. Thus, downregulation of either the 
AMPK or mTORC1 signaling pathway 
directly induces an abnormal muscle cell 
size, showing that the AMPK/mTORC1 
crosstalk constitutes a gauge essential for 
the precise adjustment of muscle cell size.
Previous studies have implicated 
mTORC1 and its downstream target 
p70S6K in the control of protein synthesis 
rate during muscle adaptation to increased 
contractile loading. During mechanically 
induced skeletal muscle growth, AMPK 
activation and phosphorylation has been 
negatively correlated with phosphorylation 
of p70S6K at the mTOR-specific Thr389 
residue (p70S6KThr389), implicating AMPK 
as a major negative regulator of overload-
induced skeletal muscle hypertrophy.11,17-19 
Recently, Paturi et al. have reported that 
insulin resistance and related comorbidi-
ties may be associated with decreases in 
the ability of muscle to undergo hyper-
trophy, and that this alteration was 
associated with decreased p70S6K Thr389 
phosphorylation and increased 
AMPKThr172 phosphorylation.20 It has also 
been reported that chronic AMPK activa-
tion by continuous infusion of AICAR 
activation of AMPK and then inhibition 
of muscle growth. Indeed, p70S6K-knock-
out mice show a robust AMPKThr172 phos-
phorylation, as well as of its downstream 
target acetyl CoA carboxylase (ACC), and 
mimic the metabolic adaptations to a low-
calorie diet.11 Moreover, knockdown of 
p70S6K in myotubes induces AMPK acti-
vation and a concurrent decrease in cell 
size, indicating that activation of AMPK 
is accountable for muscle cell atrophy.11 
Similarly, the muscle-specific knockout of 
IRS1/2 exhibits increased AMPK phos-
phorylation, associated with increased 
phosphorylation of ACC and raptor.13 All 
together, these results indicate that, while 
mTORC1 promotes muscle growth and 
protein synthesis, the role of AMPK might 
be to limit muscle hypertrophy.
As could be expected, muscle cells defi-
cient in p70S6K are resistant to a hyper-
trophic stimulus, whether it is mediated 
by nutrients, by a constitutively active 
form of Akt (MyrAkt) (an effector known 
to enhance skeletal muscle protein syn-
thesis through activation of mTORC1 
signaling) or by IGF1.14 Indeed, lack of 
a key protein of the mTORC1 pathway, 
such as p70S6K, renders the muscle cell 
unresponsive to a growth stimulus, even 
if it is able to sense it.14 Interestingly, 
most of the studies focusing on inactiva-
tion of the mTORC1 pathway in muscle 
show an increase in the phosphorylation 
of Akt (Thr308 and Ser473) in vivo.11,12,15 
Nevertheless, this activation does not have 
any effect downstream of mTORC1 and 
does not induce hypertrophy because of 
the lack of a key signaling protein down-
stream of Akt (either raptor, p70S6K or 
mTOR). The phosphorylation of Akt 
in these muscles compared with control 
muscle is likely due to the suppression 
of the inhibitory feedback of mTORC1 
on insulin signaling. The negative feed-
back involves P70S6K phosphorylation of 
IRS-1, leading to its degradation, thereby 
suppressing insulin signaling.16
To verify the counter-regulatory cross-
talk between mTORC1 and AMPK, we 
have generated muscle-specific AMPK-
deficient mice as well as AMPK-deficient 
myotubes.2 We have shown that AMPK 
deletion is sufficient to activate mTORC1 
signaling, leading to increased muscle cell 
size in cultured primary myotubes and 
encoded by different genes and give rise 
to a variety of heterotrimeric combina-
tions. The phosphorylation of a conserved 
threonine residue (Thr172) within the 
kinase domain of the α-catalytic subunit 
is absolutely required for AMPK activa-
tion by upstream kinases identified as the 
protein kinase LKB1 (a tumor suppres-
sor whose germline mutations in humans 
are the cause of Peutz-Jeghers syndrome), 
the CaMKKβ (Ca2+/calmodulin-depen-
dent protein kinase kinase β) and TAK1 
(transforming growth factor β-activated 
kinase).7 When the cellular AMP/ATP 
ratio is high, AMPK is activated, switch-
ing off ATP-consuming anabolic path-
ways and switching on ATP-producing 
catabolic pathways,7 the net result being 
suppression of protein synthesis and cell 
growth.8 In skeletal muscle, AMPK acti-
vation causes metabolic changes that assist 
muscle cells in adapting to energy depriva-
tion (hypoxia, osmotic stress, endurance 
exercise and electrically stimulated con-
traction) by increasing oxidative capacity 
via increased mitochondrial biogenesis, 
enzyme expression and nutrient uptake.9,10
Use of knockout models for upstream 
and downstream components of 
mTORC1 signaling has helped to dem-
onstrate its crucial role in the regulation 
of muscle cell size. Defects in mTORC1 
signaling have severe consequences on 
muscle cell size regulation, as revealed by 
decreased muscle mass and fiber cross-
sectional area in IRS1/2, raptor, p70S6K 
and mTOR knockout mouse models.11-15 
Downregulation of the mTORC1 signal-
ing in these models is confirmed by the 
decreased phosphorylation of downstream 
targets, such as p70S6K or 4E-BP1.11-15 
The double IRS1/2 muscle-specific knock-
out had also decreased protein content in 
the skeletal muscle, suggesting the atrophy 
in IRS1/2-deficient muscles is due, at least 
partly, to the inhibition of mTORC1-
mediated muscle growth.13 Interestingly, in 
all these models with impaired mTORC1 
signaling, AMPK is highly activated, sug-
gesting a negative crosstalk between these 
two pathways. In this context, activation 
of AMPK is induced by an increase in 
the AMP:ATP ratio.11,13 Thus, mTORC1 
signaling appears to be essential for nor-
mal ATP production, and its disruption 
clearly induces energetic stress, subsequent 
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between 4E-BP1 phosphorylation lev-
els and muscle hypertrophy.19 Our data 
confirms that, in response to mechanical 
overload, mTORC1 signaling is unaf-
fected by the presence of AMPKα2 in 
AMPKα1-deficient muscle and provides 
evidence that AMPKα1 activation lim-
its muscle mass and cell size.4 To further 
evaluate the role of AMPKα2 in the 
regulation of muscle cell hypertrophy, we 
investigated the hypertrophic action of 
MyrAkt in AMPKα2-deficient and con-
trol TA muscles. Interestingly, MyrAkt-
induced hypertrophy was slightly lower 
in muscle fibers lacking AMPKα2 than 
in control fibers but does not reach sta-
tistical significance (Fig. 2A and B). To 
address whether AMPKα2 contributes to 
the control of muscle cell size, we mea-
sured the size of myotubes isolated from 
AMPKα2-knockout and control mice. 
The diameter of AMPKα2-deficient 
myotubes was 25% smaller than control 
myotubes (Fig. 2C). Furthermore, the 
degree of cell hypertrophy in response to 
MyrAkt action is significantly lower in 
AMPKα2-deficient myotubes compared 
with control myotubes (+ 7% vs. 17% 
of AMPK have distinct functions in the 
regulation of overload-induced skeletal 
muscle hypertrophy. Consistent with this 
hypothesis, we recently reported that 
the AMPKα1 catalytic isoform plays an 
important role in the regulation of skel-
etal muscle growth. First, we showed that 
AMPKα1-deficient myotubes are larger 
than AMPKα1-expressing control cells, 
indicative of a unique role for AMPKα1 
in the control of cell size.4 Similarly, two 
recent studies have also reported a role for 
AMPKα1 in the regulation of pancreatic β 
cell size through the inhibition of mTOR 
signaling.22,23 Second, the hypertrophic 
action of MyrAkt caused a higher increase 
both in the diameter of myotubes deleted 
for AMPKα1 and in the fiber cross-sec-
tional area of AMPKα1-deficient muscle.4 
Importantly, we also demonstrated that 
overload-induced muscle hypertrophy is 
greater in AMPKα1-knockout mice com-
pared with control mice.4 We observed a 
greater increase in p70S6K and 4E-BP1 
phosphorylation in AMPKα1-deficient 
muscle compared with control during 
overload-induced hypertrophy of plantaris 
muscle,4 consistent with the correlation 
(5-aminoimidazole-4-carboxamide-1-β-
D-ribofuranoside), a potent AMPK acti-
vator, inhibits overload-induced muscle 
hypertrophy.21 In order to determine the 
role of AMPK on mTOR-induced muscle 
hypertrophy, we analyzed the hypertro-
phic action of MyrAkt in AMPK-deficient 
and control tibialis anterior (TA) muscle 
(Fig. 1A). The cross-sectional area (CSA) 
of TA fibers was significantly increased but 
was more pronounced in AMPK-deficient 
muscle, in which the CSA was 32% larger 
than in control muscle (Fig. 1B and C). 
These data indicate that AMPK acts as a 
negative feedback control to restrain mus-
cle hypertrophy.
Interestingly, McGee et al. have 
recently shown that skeletal muscle hyper-
trophy is normal in response to chronic 
mechanical overload in the absence of 
LKB1, the primary upstream kinase for 
AMPK in muscle. In this context, skel-
etal muscle hypertrophy is associated with 
a marked activation of AMPKα1, which 
still occurs in LKB1-deficient muscle, 
whereas the activity of AMPKα2 is com-
pletely abolished.3 These data suggest 
that the α1 and α2 catalytic isoforms 
Figure 1. increased hypertrophic response in AMPK-deficient muscle fibers. (A) AMPKα1 and AMPKα2 protein expression in tibialis anterior (tA) 
muscle from AMPKα1+/+α2+/+ HSA-Cre+ and AMPKα1-/-α 2fl/fl HSA-Cre+ mice. (B) Cross-sectional area (CSA) of AMPKα1+/+α2+/+ HSA-Cre+ and AMPKα1-/-α2fl/ fl 
HSA-Cre+ tA myofibers transfected with MyrAkt. MyrAkt (HA-tagged MyrAkt)-transfected myofibers were visualized by immunostaining with anti-HA 
antibody. Positive cells are marked with a star in the representative image. (C) Myofiber hypertrophy is represented as percent change to GFP-trans-
fected myofibers CSA. tA muscles from α1+/+α2+/+ HSA-Cre+ or α1-/-α2fl/fl HSA-Cre+ mice were transfected by electroporation with plasmids encoding 
MyrAkt or GFP as control. the muscle was removed ten days later and muscle fiber CSA was analyzed. the CSA was obtained from at least three differ-
ent muscle areas of four animals in each group. results are presented as means ± SD, ##p < 0.01 vs. wt.
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was also reported during exercise in skel-
etal muscle of AMPKα2-knockout mice.29 
Clearly, more experiments are required to 
delineate the additional mechanism(s) by 
which AMPKα2 deficiency resulted in an 
attenuated hypertrophic response.
The catalytic AMPKα1 isoform has 
been shown to be preferentially activated 
following overload-induced hypertrophy 
without causing metabolic adaptations 
(without any change in mitochondrial 
mass or GLUT4 expression), suggesting 
increase cell size depends on the activity 
of mTOR24 and the increase in intracel-
lular ATP level to activate the mTOR 
signaling.25 It has been proposed that 
mTOR activity requires high intracel-
lular ATP concentrations due to its rela-
tively high K
m
 for ATP.26 Defect in ATP 
production has been observed in mice 
expressing a kinase-dead AMPKα2 sub-
unit in skeletal muscle following chronic 
energy deprivation27 and exercise.28 In 
addition, a marked energy disturbance 
respectively; Fig. 2C). This was associ-
ated with a lack in increased p70S6K 
phosphorylation in AMPKα2-deficient 
mytotubes following MyrAkt expres-
sion (Fig. 2D). Taken together, these 
results suggest that hypertrophic action 
of MyrAkt is impaired in the absence of 
AMPKα2. Since growth requires ATP, 
one possibility is that AMPKα2 deficiency 
limits ATP generation for cell growth in 
response to MyrAkt-induced hypertrophy. 
Particularly, the ability of Akt activity to 
Figure 2. Cell size control in muscle cells lacking AMPKα2. (A) Skeletal muscle fiber hypertrophy is evaluated with variations in size of CSA of wt and 
AMPKα2-/- myofibers overexpressing MyrAkt in tA muscle, represented as percent change to non-transfected myofibers CSA. the CSA of myofibers was 
determined from at least four different muscle areas of four animals in each group. (B) MyrAkt (HA-tagged MyrAkt)-transfected myofibers were visual-
ized by immunostaining with anti-HA antibody. Positive cells are marked with a star in the representative image. (C) Primary muscle cells isolated from 
AMPKα2-/- and control mice were differentiated into myotubes. wt and AMPKα2-/- myotubes were transduced with 75 moi GFP and MyrAkt adenovirus-
es as indicated. Size of myotubes is presented as a percentage of wt muscle cells transduced with GFP adenovirus. Size of myotubes was measured in 
a region where myonuclei were absent and diameter was constant. (D) thr389p70S6K phosphorylation was determined 2 days after infection. results are 
presented as a percentage of wt and AMPKα2-/- muscle cells transduced with GFP adenovirus, respectively. Data from four experiments on three dif-
ferent cultures are shown in (C and D). results are represented as means ± SD in (A, C and D). Different from GFP cells of the same genotype, $$p < 0.01,  
$$$p < 0.001; Different for the same conditions of infection, ##p < 0.01.
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muscle metabolism12 in addition to protein 
synthesis suggest that AMPK’s metabolic 
effects might be mediated, at least in part, 
through modulation of mTORC1 activ-
ity and vice versa. It has been proposed 
that the mTORC1-AMPK gauge adjusts 
muscle plasticity to environmental signals 
by altering the glycolytic-oxidative prop-
erties of the muscle.11 All muscle types 
seem to be equally affected by p70S6K 
deficiency, which induces a shift toward 
an oxidative metabolism without affecting 
myosin expression.11,14 In contrast, oxida-
tive muscles are the most affected by rap-
tor deficiency and behave metabolically 
like fast-twitch glycolytic muscles while 
exhibiting structural features and contrac-
tion properties indicative of slow-twitch 
oxidative muscle fibers.12 Loss of mTOR 
in muscle results in a myopathy similar to 
that observed in raptor-deficient muscles, 
but the observed pathology is more severe 
and affects all muscle types.15 However, 
fast-twitch muscles are the most affected 
by mTOR deficiency regarding mass and 
cross-sectional area reduction. Similar to 
raptor-deficient muscles, muscles lack-
ing mTOR have an impaired oxidative 
function as well as increased slow myo-
sin expression.15 Interestingly, AMPK 
also appears to be an important mediator 
preferentially activated in response to 
acute exercise35-37 or endurance training,38 
whereas low intensity contraction and 
oxidative stress activate AMPKα1 in skel-
etal muscle.39-41 Interestingly, it has been 
shown that twitch contraction stimulates 
glucose uptake through AMPKα1 acti-
vation but not AMPKα2.42 AMPKα1 
activation was not accompanied by an 
increase in AMP level or AMP/ATP 
ratio, suggesting that AMPKα1 activa-
tion induced by low-intensity contraction 
is regulated by an AMP-independent40,41 
and/or LKB1-independent mechanism.43 
Accordingly, LKB1 appears to be essential 
for AMPKα2 activity in different muscle 
types, whereas AMPKα1 activity is only 
partially affected in LKB1-deficient skele-
tal muscle.3,44,45 CaMKK and TAK1 could 
therefore be the upstream kinases respon-
sible for AMPKα1 activation during over-
load-induced muscle hypertrophy.3
AMPK has emerged over the last 
decade as a central integrator of signals 
that control energy balance. Our results 
extend this notion by showing that 
AMPKα1 but not AMPKα2 controls 
muscle cell size and is involved in the cell 
size maintenance through the regulation 
of mTORC1 signaling (Fig. 3). The recent 
findings that mTORC1 regulates skeletal 
that AMPKα1 might be more important 
in growth than in metabolism regula-
tion.3 These data indicate that AMPKα1 
and α2 catalytic isoforms perform diverse 
functions, with AMPKα1 playing a pre-
dominant role in the control of cell size 
and AMPKα2 primarily involved in 
energy metabolism regulation. Indeed, 
skeletal muscle metabolic adaptation pref-
erentially occurs through the activation 
of AMPKα2 rather than AMPKα1.30-32 
While AMPKα1 activity is similar in 
muscle from lean and obese animals and 
is unaffected by rosiglitazone, AMPKα2 
activity was 25% lower in obese vs. lean 
animals and was normalized to control 
values after rosiglitazone treatment.33 
Abbott et al. have shown that AICAR, 
caffeine and muscle contraction increase 
AMPKα2 activity but do not affect 
AMPKα1 activity in skeletal muscle.34 In 
contrast, Egawa et al. have shown that of 
the two AMPK α isoforms, AMPKα1 is 
most activated by caffeine in rat skeletal 
muscle both ex vivo and in vivo through 
an energy-independent mechanism asso-
ciated with increased ACC phosphoryla-
tion and glucose transport. Furthermore, 
recent evidence indicates that AMPKα1 
and AMPKα2 isoforms are differen-
tially activated. AMPKα2 appears to be 
Figure 3. the AMPK/mtOrC1 gauge tightly controls muscle cell size. AMPKα1 and α2 catalytic isoforms perform diverse functions in skeletal muscle. 
in response to energy deprivation, AMPKα2 is activated by LKB1 to regulate metabolic adaptation of skeletal muscle, whereas, in response to mechani-
cal overload, AMPKα1 is activated by CaMKK to control muscle cell size. AMPKα1 inhibits mtOrC1 signaling by the direct phosphorylation of raptor, 
mtOr and tSC1/tSC2, consequently shutting down protein synthesis and muscle cell growth. On the other hand, activation of mtOrC1 in response to 
resistance exercise or under high nutritional status inhibits AMPK activity by affecting intracellular energy levels and stimulates protein synthesis by 
the phosphorylation of p70S6K and 4e-BP1, effectively promoting muscle cell growth.
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